Compare AbbVie Inc (ABBV) vs Crowdstrike Holdings Inc (CRWD) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

CrowdStrike (CRWD) trades at $194.62, up 0.43% today, with a strong technical outlook showing bullish momentum and key resistance at $199. The stock recently completed a 4-for-1 split, enhancing accessibility. Revenue growth accelerated to 26% year-over-year in Q1 2026, with EPS consistently beating estimates, though net margins remain negative. Analyst sentiment is overwhelmingly positive with 76% buy ratings and a $180.33 consensus target, despite premium valuations like a P/E of 765.

Outlook remains optimistic due to robust cybersecurity demand and AI-driven threats, but high valuation and profitability challenges pose risks. Investors should weigh growth potential against elevated multiples and competitive pressures in the sector.